Loxbridge Research, Royal Institution of Great Britain, London W1S 4BS, UK.
Anal Biochem. 2013 Dec 1;443(1):97-103. doi: 10.1016/j.ab.2013.08.019. Epub 2013 Aug 28.
The development of diagnostic assays using highly targeted specific aptamers with existing detection platforms has been an endeavor with few opportunities until now. Many current commercially available diagnostic platforms make use of detection systems employing capture agents composed of modified antigen-specific antibodies coupled with a variety of detection modalities, including radioimmunoassays, fluorescence-based detection assays, electro/chemiluminescence assays, and immunoradiometric assays. In the studies presented here, a novel frequency-modulating technology from BioScale called Acoustic Membrane MicroParticle (AMMP) detection was used to demonstrate a sensitive and reproducible method of incorporating aptamers as capture and detection agents. The method provides a robust and rapid detection of thrombin in human serum while also eliminating the labor-intensive efforts of Western blot analysis and is not affected by the interfering substances found in serum that often affect optical-based detection systems. In addition, we have demonstrated, for the first time, the adaptation of the AMMP platform to exploit aptamers against a clinically relevant target. The AMMP platform is an ideal medium for using aptamers in commercial assay development for application in a clinical setting.
利用现有的检测平台开发针对高度靶向特定适体的诊断检测方法，迄今为止一直机会寥寥。许多当前市售的诊断平台利用检测系统，这些系统采用由经过修饰的抗原特异性抗体与各种检测模式（包括放射免疫测定、基于荧光的检测测定、电化学发光测定和免疫放射测定）偶联的捕获剂。在本文呈现的研究中，一种来自 BioScale 的新型频率调制技术，即声膜微颗粒（AMMP）检测，被用于展示将适体作为捕获和检测剂的灵敏且可重现的方法。该方法提供了对人血清中凝血酶的灵敏和可重现的检测，同时消除了 Western blot 分析的劳动密集型工作，并且不受经常影响基于光学的检测系统的血清中的干扰物质的影响。此外，我们首次展示了 AMMP 平台适应针对临床相关靶标的适体的能力。AMMP 平台是在临床环境中应用于商业检测开发中使用适体的理想媒介。
